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Abstract  
Impaired Ectodysplasin A (EDA) – Eda receptor (EDAR) signaling affects ectodermally derived 
structures including teeth, hair follicles and cutaneous glands. X-linked hypohidrotic ectodermal 
dysplasia (XLHED), resulting from EDA deficiency, can be rescued with lifelong benefits in animal 
models by stimulation of ectodermal appendage development with EDAR agonists. Treatments 
initiated later in the developmental period restore progressively fewer of the affected structures, 
and it is unknown whether EDAR stimulation in adults with XLHED might have beneficial effects. We 
find that sebaceous glands of adult Eda mutant mice enlarge slowly when administered an agonist 
anti-EDAR antibody, are maintained in an enlarged state upon chronic treatment, but regress slowly 
over a period of weeks upon cessation of treatment. Sebaceous glands in all skin regions respond to 
treatment, though to varying degrees, and this is accompanied in both Eda mutant and wild type 
mice by sebum secretion to levels higher than those observed in untreated controls. Edar is 
expressed at the periphery of the glands, suggesting a direct homeostatic effect of Edar stimulation 
on the sebaceous gland. Sebaceous gland size and sebum production may serve as biomarkers for 
EDAR stimulation, and EDAR agonists may improve skin dryness and eczema frequently observed in 
XLHED.  
 
Introduction 
Hypohidrotic ectodermal dysplasia (HED) is a congenital condition defined by reduced or absent 
development of teeth, hair follicles and cutaneous glands, notably the eccrine sweat glands (Clarke 
1987, Clarke, Phillips et al. 1987, Wright, Grange et al. 1993). This condition is caused by defects in 
signaling from the transmembrane receptor EDAR, most commonly due to mutation of the gene 
encoding its ligand, EDA, which lies on the X-chromosome (Kere, Srivastava et al. 1996), or caused by 
mutation of the EDAR gene itself (Monreal, Ferguson et al. 1999) or affecting its intracellular adapter 
protein EDARADD (Headon, Emmal et al. 2001). Absence or reduced function of this TNF-like 
pathway leads to failure to activate NF-B, which is required for initiation of appendage 
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development and control of morphogenesis (Doffinger, Smahi et al. 2001, Schmidt-Ullrich, Aebischer 
et al. 2001). 
 
Most individuals with HED are males with the X-linked form (XLHED), caused by mutation of the EDA 
gene. Although few systematic reports of HED incidence exist, a recent Danish study estimated the 
frequency of XLHED at between 1.6 and 21.9 per 100,000 population, depending on the stringency 
of diagnostic criteria applied (Nguyen-Nielsen, Skovbo et al. 2013). Much of the ongoing 
management of XLHED-affected patients centers on ameliorating the symptoms of glandular 
dysfunction in the skin and mucosae. This management includes provision of lubrication to the eyes 
to compensate for reduction of Meibomian and lacrimal gland secretions (Reed, Lopez et al. 1970, 
Tyagi, Tyagi et al. 2011, Dietz, Kaercher et al. 2013), administering artificial saliva due to xerostomia 
arising from salivary gland reduction (Daniel, McCurdy et al. 2002), removal of nasal and otic crusting 
(Callea, Teggi et al. 2013) and application of emollient to improve dry skin and eczema symptoms 
(Chen 2006, Tyagi, Tyagi et al. 2011). External cooling during physical exertion or in hot weather may 
also be needed due to reduced or absent sweating (Hammersen, Neukam et al. 2011, Schneider, 
Hammersen et al. 2011). 
 
Since the identification of the EDAR pathway, a number of reagents to modulate its signaling have 
been developed. Pathway stimulation can be achieved using a modified form of recombinant EDA 
consisting of its C-terminal TNF domain fused to an immunoglobulin Fc domain (Gaide and Schneider 
2003). Acting in a manner analogous to that of the endogenous ligand, monoclonal antibodies that 
bind the EDAR extracellular domain also stimulate this pathway (Kowalczyk, Dunkel et al. 2011), 
presumably by causing clustering and activation of the receptor, while suppression of the EDA signal 
may be achieved by blocking monoclonal antibodies directed against the ligand's receptor binding 
domain (Kowalczyk-Quintas, Willen et al. 2014). 
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In the mouse, mutation of any of the Eda, Edar or Edaradd genes leads to a phenotype analogous to 
the human condition, with defective development of teeth, glands and certain types of hair follicles 
(Srivastava, Pispa et al. 1997, Headon and Overbeek 1999, Headon, Emmal et al. 2001). The 
morphological defects caused by Eda mutation can be rescued by prenatal or perinatal 
administration of recombinant Fc-EDA protein (Gaide and Schneider 2003, Casal, Lewis et al. 2007), 
or ligand replacement using an EDAR agonist antibody (Kowalczyk, Dunkel et al. 2011), as 
demonstrated in mouse and dog models of XLHED. These therapeutic effects have lifelong benefit, 
but are achieved only if ligand is administered during a developmental window appropriate for a 
particular structure. Treatment after the developmental window had no detectable effect on the 
parameters examined. For example, shape of the first molar is rescued only if Fc-EDA is administered 
to mice before embryonic day 15 (Gaide and Schneider 2003). Unknown, however, is whether 
dynamic structures which undergo continual cell proliferation might benefit from chronic EDAR 
stimulation in adult life. 
 
The sebaceous glands undergo constant cellular turnover throughout life, driven by proliferation of 
the flattened cells at the gland’s periphery. The daughter cells thus produced move to the center of 
the gland, swelling as they accumulate and modify lipids until cellular rupture and release of the 
sebum into the hair canal or onto the skin surface (Niemann and Horsley 2012). The sebum itself is a 
complex lipid mixture composed primarily of triglycerides, cholesterol and wax esters which acts to 
aid skin barrier function and humidification (Fluhr, Mao-Qiang et al. 2003, Fluhr, Darlenski et al. 
2008), modulate the skin microflora (Fischer, Blanchette et al. 2013), deliver antioxidants to the skin 
surface (Thiele, Weber et al. 1999) and maintain the hair follicles (Zheng, Eilertsen et al. 1999, 
Sundberg, Boggess et al. 2000, Stenn 2001). Altered sebaceous gland activity is implicated in the 
pathogenesis of a number of dermatological conditions, including acne vulgaris (Zouboulis, Jourdan 
et al. 2013), some forms of dermatitis (Gary 2013) and rosacea (Raghallaigh, Bender et al. 2012), 
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while reduced sebaceous function may be causative in hidradenitis suppurativa (Kamp, Fiehn et al. 
2011) and scarring alopecia (Al-Zaid, Vanderweil et al. 2011). 
 
A characteristic of XLHED is that the sebaceous glands are sparse and hypoplastic, this likely being 
the underlying cause of the dry skin and susceptibility to eczema in this condition (Reed, Lopez et al. 
1970, Daniel, McCurdy et al. 2002). In the EdaTa (Tabby mutant) mouse model of XLHED the 
sebaceous glands are reduced (Gruneberg 1971), while constitutive expression of an Eda transgene 
causes an increase in sebaceous gland size (Cui, Durmowicz et al. 2003, Mustonen, Pispa et al. 2003). 
Cui et al. (Cui, Durmowicz et al. 2003) have shown that persistent expression of Eda throughout 
development and postnatal life leads to sebaceous gland hyperplasia, but that subsequent 
suppression of Eda expression in the adult is followed by sebaceous gland reduction over a period of 
months. This demonstrates an impact of Eda signaling on mature sebaceous gland function, though 
whether this impact can be achieved when the Edar pathway is activated for the first time in the 
adult, never having been active during development, is unknown. 
 
The generation of reagents that allow time-limited modulation of EDAR activity at any stage of life 
(Gaide and Schneider 2003, Kowalczyk, Dunkel et al. 2011, Kowalczyk-Quintas, Willen et al. 2014), 
and the onset of clinical trials to assess the potential of these medicines to treat XLHED and some 
forms of autosomal HED, have prompted us to assess the responses of adult sebaceous glands to 
activation of this pathway. We find corrective effects at morphological and functional levels upon 
Edar stimulation in adult XLHED animals, demonstrating that at least some adult tissues retain an 
ability to respond to chronic EDAR stimulation with potential therapeutic benefit and also serving as 
a biomarker of EDAR stimulation in vivo. 
 
Results 
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Rescue of sebaceous gland size in adult mice by treatment with Edar-agonist antibody  
We began by assessing whether there is a detectable morphological response of sebaceous glands to 
administration of the EDAR agonist monoclonal antibody mAbEDAR1 (Kowalczyk, Dunkel et al. 
2011). EdaTa mice received intraperitoneal administrations of 2 mg/kg mAbEDAR1 starting at 
postnatal day 12 (P12), a time point when no developmental rescue of hair, sweat glands and teeth 
can be obtained (Gaide and Schneider 2003). Treatments were performed weekly for 24 weeks and 
tissue samples collected at 26 weeks of age, together with skin from untreated EdaTa, from wild type 
mice, and from treated EdaTa mice in which treatment was terminated 6 weeks prior to analysis to 
assess whether any effect obtained would be reversible in this time period (Figure 1a). Sebaceous 
gland size was determined in sections of facial skin (Figure 1b) and measured to determine 
aggregate gland size relative to skin length (Figure 1c). Untreated EdaTa mutants had hypoplastic 
sebaceous glands, with an aggregate sebaceous gland size less than half that of wild type animals, 
while systemic treatment of this mutant line with mAbEDAR1 completely rescued gland size. This 
rescue persisted for at least one month after cessation of antibody administration. In order to 
determine the basis of increased sebaceous gland size in the treated animals, we measured sebocyte 
size in all conditions (Figure 1d). This parameter was unchanged across treatments and genotypes, 
indicating that reduced gland size in EdaTa skin is due to a lack of sebocytes, rather than these cells 
being smaller than normal. Rescue of sebaceous gland size by mAbEDAR1 administration was thus 
achieved by increasing cell number to that of wild type mice. 
 
Dynamics of sebaceous gland response to Edar stimulation 
In order to obtain a dynamic view of sebaceous gland responses to mAbEDAR1 administration and 
withdrawal, we initiated treatment of EdaTa mutant and wild type animals at weaning (between 21 
and 26 days of age, i.e. later than P12, and in the adult hair cycle, to further exclude any contribution 
of developmental processes) with 2 mg/kg mAbEDAR1 and then either re-administered every second 
week until tissue collection or else maintained animals with no further administration (Figure 2a). 
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Untreated animals were maintained as controls. We devised a more rapid processing method to 
measure sebaceous gland size. This involved visualization of sebaceous glands in ear skin using 
collagenase to remove dermal tissue followed by staining for lipid using Oil Red-O, a process that 
reveals sebaceous glands as paired kidney-shaped structures around the hair follicles (Figure 2b). 
 
Measurement of average sebaceous gland size per hair follicle in the ear revealed that gland size is 
smaller in EdaTa than wild type animals across the experimental time course from 2 to 24 weeks 
post-weaning (Figure 2c), as expected. Gland sizes are relatively stable at different ages in adult skin, 
though with a trend to reduced size in older individuals. Treatment with mAbEDAR1 did not have a 
detectable effect on either EdaTa or wild type sebaceous glands after two weeks, but by six weeks an 
enlargement was detectable in EdaTa skin (Figure 2d). With twelve weeks of continual treatment, 
involving 6 administrations in total, the EdaTa glands had attained the size observed in wild type, 
while treated wild type animals only displayed a non-significant increase in gland size (Figure 2e). 
Similar effects were observed in ear skin of EdaTa mice treated for 6 months with mAbEDAR1 (Figure 
1a and data not shown). The effects of a single administration to EdaTa were long-lived, being 
detectable at the morphological level 12 weeks later, but not anymore at 24 weeks (Figure 2d). Thus, 
despite this long-lived effect, maintenance of sebaceous rescue requires chronic treatment (Figure 
2d). 
 
Sebaceous glands in dorsal skin are highly responsive to Edar stimulation  
To determine whether sebaceous glands in the more intensively studied dorsal skin respond in the 
same manner as in ear skin to mAbEDAR1 administration, we analyzed gland size in skin sections at 
the 12 weeks time point. Clear differences between continually treated and single and untreated 
animals in the size of the sebaceous glands were apparent in the sections (Figure 3a). We 
determined aggregate sebaceous gland size in EdaTa skin to be about half that of wild type, but 
chronic treatment with mAbEDAR1 stimulates a large increase in the size of both mutant and wild 
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type glands. Similar to what was observed in the ear, a single administration of mAbEDAR1 was less 
efficient than chronic treatment to increase sebaceous gland size 12 or 24 weeks later (Figure 3b). 
The response in dorsal skin appears less limited than in the ear skin as we measured at 12 weeks 3.1-
fold and 6.9-fold increases for dorsal skin sebaceous glands of wild type and EdaTa mice (Figure 3b), 
compared to 1.4-fold and 2.3-fold increases in ear skin sections (Figure 3c).  
 
Edar expression in mature sebaceous glands 
To identify the likely cellular target stimulated by the mAbEDAR1 monoclonal antibody, we assessed 
which cell types in adult dorsal skin express the Edar gene. In situ hybridization of adult mouse skin 
in anagen phase revealed Edar expression at the periphery of the sebaceous glands, but occasionally 
also on sebocytes in wild type animals but not in EdarOVE1B/OVE1B mice lacking all Edar exons (Headon 
and Overbeek 1999) (Figure 4a), suggesting that antibody driven sebaceous gland enlargement is 
achieved by direct stimulation of the glands.  
 
EDAR stimulation induces proliferation of sebocyte precursors 
Eda-deficient mice that were treated for one or three weeks with buffer only or mAbEDAR1 were 
given BrdU two hours before sacrifice. Proliferation-specific Ki67 and BrdU stainings were successful 
as witnessed by labeling of intestinal crypts, a site of intense cell proliferation (Figure 4b). In skin, 
some BrdU-positive and a greater number of Ki67-positive cells were detected in the epidermis, in 
hair follicles (data not shown) and in the pilosebaceous unit, in particular at the periphery of 
sebaceous glands (Figure 4c). In line with our previous results, after one week of treatment, there 
was no significant change in gland size, but this difference was obvious in mice treated for 3 weeks 
(Figure 4d).  At 3 weeks, both the number and percentage of Ki67-positive cells at the periphery of 
sebaceous glands was higher in treated mice than in control (Figure 4d,e). Interestingly, in four 
weeks-old mice (at 1 week of treatment), most cells at the periphery of sebaceous glands were 
proliferating regardless of treatment. These data suggest that the enlargement of sebaceous glands 
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observed after treatment may be due to sustained proliferation of sebocyte precursors at the 
periphery of sebaceous glands. 
 
Functional enhancement of adult sebaceous gland activity by Edar stimulation 
In order to determine whether the morphological increase in sebaceous glands is accompanied by 
increased function, we determined sebum output in treated and untreated EdaTa and wild type mice. 
Mice at weaning were treated every second week for 6, 12 or 24 weeks with mAbEDAR1, which we 
have established here to increase sebaceous gland size; mAbEDAR3, an independent Edar agonist 
monoclonal antibody (Kowalczyk, Dunkel et al. 2011); and Aprily2, an unrelated isotype-matched 
monoclonal antibody serving as a negative control (Schwaller, Schneider et al. 2007) (Figure 5a). 
First, we noted that mice treated with Edar agonists have a disheveled and greasy appearance 
(Figure 5b), which might be contributed to by increased sebum production from the enlarged glands. 
We then assayed sebum deposition onto the dorsal hairs in treated and untreated animals using thin 
layer chromatography to separate sebum components. Chromatography revealed that hair from 
mAbEDAR1- and mAbEDAR3-treated animals carries more sebum than that from untreated or 
Aprily2-treated animals, this effect being particularly notable in the wax diester fraction, but also 
significant in the faster and slower migrating bands (Figure 5c,d). This confirms that the 
morphological increase in sebaceous gland size is accompanied by increased sebum production, and 
this results from Edar pathway stimulation rather than a non-specific effect of monoclonal antibody 
administration. At the 6 weeks time point, untreated Eda-deficient mice had less sebum than wild 
type, but this difference was no longer observed 6 weeks later (Figure 5e). Also, there was 
consistently more sebum in older mice (12 and 24 weeks time points) than in younger ones (6 
weeks), a difference that was still visible in treated mice (Figure 5f). No significant differences were 
observed between sebum of males and females. Analysis by electrospray mass-spectrometry of 
three sebum per condition revealed, among other lipids, the presence of lanosterol, cholesterol 
esters, wax monoesters (C42 to C50), a major species of wax diester (C60), mostly saturated 
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triacylglycerols (TAGs) and O-alkyl TAGs (C50 to C62), and a prominent species of polyunsaturated 
TAG (C58) (Supplementary Figures 1 and 2). Although treatment clearly increased the amount of 
sebum, sebum components and their fine composition were remarkably similar between wild type 
and Eda-deficient mice, before and after treatment, suggesting that EDAR stimulation increases the 
number of sebocytes more than their function. One exception was the polyunsaturated C58 TAG 
that, although present in untreated Eda-deficient mice, was not induced by treatment in the three 
independent samples analyzed (Supplementary Figure 1 and data not shown). 
 
Discussion 
Ectodermal dysplasias in human and in animal models are identifiable in the early postnatal period 
due to impairment of prenatal developmental processes. Rarely addressed is the question of 
whether tissue homeostasis is also controlled by EDAR pathway signaling, allowing a potential for 
therapeutic effects of Edar agonists administered to HED patients outside of the neonatal period. 
With the advent of reagents allowing time-limited modulation of the EDAR pathway (Kowalczyk-
Quintas and Schneider 2014), we can now assess adult tissue responses to modulation of this 
pathway and their kinetics. We report that adult sebaceous glands respond to EDAR stimulation, 
with no apparent need for developmental stimulation to achieve this response. A developmental 
effect that might reduce sebaceous gland size in XLHED, such as laying out of a smaller number of 
responding progenitor cells in prenatal skin, does not appear to occur and in almost all cases the 
treated EdaTa glands attain the same size as the treated wild type glands. We went on to define the 
kinetics of this morphological response, finding that this homeostatic effect is slow to appear and 
slow to revert, but that chronic treatment is required for maintenance. The half-life of mAbEDAR1 in 
mouse, as measured by its ability to bind EDAR, is estimated to be eleven days (Kowalczyk, Dunkel et 
al. 2011), this protein stability presumably having some impact on the delayed reduction in size 
following withdrawal, together with the cellular turnover rate of the sebaceous gland itself. 
Although sebaceous glands in different regions of the skin responded to Edar stimulation and 
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withdrawal in the same manner, the magnitude of changes was different, with a relatively low limit 
on the amount of enlargement seen in ear skin, while dorsal and facial skin show greater increases in 
gland size. These regional differences in response may arise from differences in local Eda or Edar or 
Edaradd expression levels, or from the presence of different numbers of progenitor cells that can 
respond to the treatment in glands from different locations. 
 
A number of genes and processes known to be targeted by Edar signaling during early hair follicle 
development are also known to influence adult sebaceous gland function, potentially representing a 
single molecular mechanism for Edar action in both developmental and homeostatic situations. 
Sonic hedgehog expression is stimulated by Edar activity in hair follicle placodes from embryonic day 
13 (Schmidt-Ullrich, Tobin et al. 2006, Pummila, Fliniaux et al. 2007), and hedgehog signaling is 
known to promote sebaceous gland development and hypertrophy (Allen, Grachtchouk et al. 2003). 
The function of Edar signaling to suppress BMP activity (Mou, Jackson et al. 2006, Pummila, Fliniaux 
et al. 2007) may also be involved as BMPs are known suppressors of sebaceous gland size (Plikus, 
Wang et al. 2004).  As sebocyte size is not affected by Edar stimulation, the change in balance of 
these, and perhaps other signals, is likely to promote sebaceous progenitor proliferation as an 
underlying mechanism for glandular enlargement in these experiments, in line with the observed 
increased percentage of Ki67-positive cells in stimulated glands. However, the preferential 
stimulation of wax diester production in sebum may additionally indicate a direct action of Edar 
signaling on sebocytes. Whatever the mechanism, sebaceous gland responses can serve as a 
sensitive biomarker for EDAR pathway stimulation in future clinical and experimental studies. 
 
This report shows that chronic Edar stimulation in an animal model of adult XLHED has corrective 
effects on at least one gland type. The restoration of sebaceous function in XLHED may improve the 
dry and eczematous skin frequently observed in this condition (Reed, Lopez et al. 1970, Daniel, 
McCurdy et al. 2002, Chen 2006, Tyagi, Tyagi et al. 2011). As chronic Edar stimulation in both Eda-
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deficient and -proficient mice boosted sebum output far above levels produced by untreated wild 
type mice, substantial improvement of sebum production may be expected even in patients with 
reduced numbers of sebaceous glands due to reduced hair follicle density. It is also possible that 
EDAR pathway stimulation is capable of stimulating growth and function of other glands affected by 
XLHED for therapeutic effect. Thus glands present but reduced in function in XLHED, such as salivary 
and lacrimal glands, may respond in a similar manner to EDAR stimulation in the adult period to 
achieve functional benefit to dry eye and xerostomia (CKQ, SS and PS, unpublished preliminary 
observations). In addition, although null mutations of EDA lead to absence of Meibomian, eccrine 
and tracheal glands, some cases of XLHED likely involve strongly hypomorphic mutations that allow a 
rudimentary gland to form during development. For example, while the EdaTa mouse carrying a 
deletion in Eda has no sweat gland structures at all (Gruneberg 1971, Gaide and Schneider 2003), a 
substantial fraction of people with diagnosed XLHED do have some sweat gland structures and a 
subset also have low level sweat production (Schneider, Hammersen et al. 2011). Such glandular 
rudiments may not be sufficient to allow full physiological activity, but may be brought to increased 
function and therapeutic benefit by chronic pharmacological EDA pathway activation, analogous to 
the responses of the hypoplastic sebaceous glands reported here. Indeed, it is emerging that a 
spectrum of EDA mutations of different severity, from null mutations causing full XLHED syndrome 
to mutations causing non-syndromic tooth agenesis (Mues, Griggs et al. 2009, Mues, Tardivel et al. 
2010) exist and also interact with modifier alleles in the genetic background (Cluzeau, Hadj-Rabia et 
al. 2012). Thus stimulation of the Edar pathway in adult life may have benefit for XLHED and for 
other conditions affecting cutaneous glands. 
 
Materials and Methods 
 
Animals and antibody administration 
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Mice carrying the Tabby mutation, which is a deletion of the first exon and promoter region of the 
Eda gene, and their wild type controls were derived from breeder pairs of B6CBACa-Aw-J/A-EdaTa/O 
mice (000314; Jackson Laboratory) (Gaide and Schneider 2003). EdaTa is used here to refer to both 
homozygous EdaTa/Ta females and hemizygous EdaTa/Y males. EdarOVE1B/OVE1B mice lacking all Edar 
exons were as described (Headon and Overbeek 1999). Generation and characterization of anti-
EDAR monoclonal antibodies has been described (Kowalczyk, Dunkel et al. 2011). Aprily-2, a mouse 
IgG1 directed against human APRIL, with no cross-reaction to mouse APRIL, was used as a control 
antibody (Schwaller, Schneider et al. 2007). Antibodies in sterile PBS were administered 
intraperitoneally at a dose of 2 mg/kg. Mice were handled according to Swiss Federal Veterinary 
Office guidelines, under the authorization of the Office Vétérinaire Cantonal du canton de Vaud 
(authorization 1370.5 to PS). 
 
Tissue analyses and morphometrics 
Formalin-fixed skin tissues were dehydrated, processed and embedded in paraffin and sectioned at 8 
m thickness. After drying, slides were stained with hematoxylin and eosin, coverslipped and imaged 
using brightfield microscopy. Features on saved microscope images were measured using ImagePro 
software (MediaCybernetics). Sebaceous glands were identified by their characteristic frothy 
appearance and were circumscribed to determine their area in pixels, which was summed for each 
image. The corresponding length of skin surface for that image was measured in pixels and used to 
normalize aggregate gland area. At least 4 sections were measured to derive a mean gland size for 
that individual animal and each section used for measurement was at least 200 m away from any 
other.  
Ear skin was processed for whole mount visualization of sebaceous glands by collection of ears 
followed by separation of the outer and inner skins using forceps. Skin samples were washed in 
Hank’s Balanced Salt Solution (HBSS) and incubated for 2 h in HBSS + 5 mM CaCl2 + 1 mg/ml 
collagenase (Sigma C2674) at 37°C. Samples were then washed in PBS, fixed in 4% 
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paraformaldehyde, rinsed in 60% isopropanol and then stained in 0.5% Oil Red O in 60% 
isopropanol. After washing with 60% isopropanol, samples were stored in buffered formalin 
solution. Stereomicroscope images of the outer and inner sides of the tip of the ear samples were 
taken and 20 glands from each side of the ear were measured in pixels by circumscribing the glands 
on the images using ImagePro. A mean value for each side of the ear from each individual was 
calculated, and the mean of the outer and inner sides calculated to give a value for that animal. The 
mean ear sebaceous gland area and standard deviation was calculated for groups of mice in each 
treatment conditions.  
 
In situ hybridization 
Dorsal skin of wild type and EdarOVE1B/OVE1B adult mice, which had been depilated 14 days earlier, was 
fixed in formaldehyde, dehydrated and embedded in paraffin. Tissue sections of 5 m were cut, 
deparaffinized and processed for in situ hybridization and signal detection using the RNAScope 
system according to manufacturer’s instructions (Advanced Cell Diagnostics; Hayward, CA) (Wang, 
Flanagan et al. 2012). After color detection, sections were lightly counterstained with hematoxylin 
and coverslipped using an aqueous mountant.   
 
Analysis of cell proliferation 
EdaTa mice (3 mice per group) were treated i.p. at weaning and 2 weeks later with mAbEDAR1 at 2 
mg/kg. Two hours prior to sacrifice (at 1 and 3 weeks after treatment initiation), mice were given i.p. 
BrdU at (Sonia, Christine: amount, conc, volume, vehicle??). Back skin and small intestine were fixed, 
embedded in paraffin and immunostained with anti-BrdU (which?) or anti-Ki67 (which?) antibodies 
((some details??)). 
 
Sebum analysis 
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Hair was shaved off the dorsum, weighed (~70 mg) and sebum extracted twice by adding 1 ml 
acetone each time. The pooled acetone extracts were dried under nitrogen and sebum dissolved in 2 
µl of acetone per mg of dry hair. 6 µl of each sample (equivalent to the amount of sebum in 3 mg 
hair) was spotted on 20 x 5 cm HPTLC silica plates, with 3 µg of cholesterol, 1.2 µg of cholesterol 
oleate, and 6 µg of rapeseed oil (triglycerides) as standards. Plates were developed twice in toluene : 
n-hexane (2:1, v/v), then dried, dipped in revelation solution (10% w/v CuSO2.5H2O, 3.5% sulfuric 
acid,  3.1% phosphoric acid in methanol) and heated at 140°C until appearance of bands. The plate 
was then photographed. Intensities of rapidly (including cholesterol esters and wax monoesters), 
intermediate (wax diesters) and slowly (including cholesterol and triglycerides) migrating bands 
were measured using the ImageJ software. Animals used for sebum determination were a separate 
set from those used for measurement of sebaceous gland size.  
Electrospray-mass spectrometry analysis 
Lipid extracts were dissolved in 15 µl of chloroform : methanol (1:2) and 15 µl of acetonitrile : iso-
propanol : water (6:7:2) and analyzed with a Absceix 4000 QTrap, a triple quadrupole mass 
spectrometer equipped with a nanoelectrospray source. Samples were delivered by direct infusion 
mode (~125 nl/min) and analyzed in both positive and negative ion modes using a capillary voltage 
of 1.25 kV. MS/MS scanning (daughter, precursor and neutral loss scans) were performed using 
nitrogen as the collision gas with collision energies between 35-90 V. Each spectrum encompasses at 
least 50 repetitive scans. Tandem mass spectra (MS/MS) i.e. daughter ion scanning was performed 
with collision energies between 35-90 V. Assignment of species is based upon a combination of 
survey, daughter, precursor and neutral loss scans. The identity of cholesterol esters and 
triacylglycerol species were verified using the LIPID MAPS: Nature Lipidomics Gateway 
(www.lipidmaps.org).   
Statistics 
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Statistical analysis was performed with the Prism software using unpaired t test for the comparison 
of two samples and ANOVA with Newman-Keuls multiple comparison test for multiple samples. 
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Figure legends 
 
Figure 1. Edar stimulation in adult mice increases facial sebaceous gland size. (a) Schematic of 
experimental schedule using mAbEDAR1. Animal age is indicated above. Gray color indicates 
absence of EDAR stimulation. (b) H&E stained sections of facial skin of untreated wild type and EdaTa 
mice, and of EdaTa mice continually treated for 5 or 6 months, with analysis at 6 months. Details of 
sebaceous glands (red dashed lines) are shown on the right. Glands are smaller in EdaTa than wild 
type. Both continual and 1-month ceased treatment fully rescues gland size. Scale bars indicate 100 
m. (c) Quantification of sebaceous gland size on sectioned facial tissues. (d) Quantification of 
sebocyte size as defined by number of nuclei per unit sebaceous gland area. This is unchanged by 
condition. Error bars indicate standard deviation. 
 
Figure 2. Chronic Edar stimulation rescues EdaTa ear sebaceous glands. (a) Schematic of 
experimental schedule. Weeks since beginning of treatment are indicated above. (b) Oil-Red-O 
staining of sebaceous glands in ear skin. Conditions as indicated. Scale bar: 250 m. Enlarged insets 
have edge lengths of 250 m. (c) Sebaceous gland size in untreated EdaTa and wild type. (d) Effects 
of mAbEDAR1 administration on sebaceous gland size of EdaTa mice. Untreated gland sizes as in 
panel c. By 6 weeks post-treatment gland size is increased. Sustained treatment is required to 
achieve full rescue. (e) Effects of mAbEDAR1 treatment on wild type sebaceous glands. Untreated 
gland sizes are as in panel c. Adjacent data bars with no p-value indicate p>0.05. Error bars indicate 
standard deviation. 
 
Figure 3.  Chronic stimulation of Edar signaling greatly stimulates sebaceous gland enlargement in 
EdaTa and wild type dorsal skin. (a) H&E stained tissue sections of dorsal skin of EdaTa and wild type 
mice either untreated, treated once only at weaning or treated every 14 days from weaning for 12 
weeks. Insets show examples of sebaceous glands at higher magnification. Scale bars indicate 100 
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m. (b) Quantification of aggregate sebaceous gland size per unit length of dorsal skin. (c) Same as 
panel b, but for ear skin at 12weeks processed in the same way. Error bars indicate standard 
deviation.  
 
Figure 4. Edar expression in adult skin. (a) Skin sections of the indicated mice with hair follicles in 
anagen phase were hybridized with Edar probe or with the negative control probe set (targeting the 
dapB gene from B. subtilis). In situ hybridization detects Edar transcripts as red dots at the periphery 
of wild type, but not Edar-deficient (EdarOVE1B/OVE1B) sebaceous glands (black arrows). A negative 
control probe set (targeting the dapB gene from B. subtilis) does not yield signal around the 
sebaceous glands in wild type skin. (b) Ki67 and BrdU immunostainings of small intestine villi. (c)  
Ki67 and BrdU immunostainings of representative sebaceous glands (highlighted by the dotted red 
line) in adjacent sections of skin of mice treated or not for 3 weeks with anti-EDAR mAb. (d-f) 
Quantification of gland area (d), number of Ki67-positive cells at the periphery of sebaceous glands 
(e), and percentage of cells that are Ki67-positive at the periphery of sebaceous glands (f) in Eda-
deficient mice treated for 1 or 3 weeks with anti-EDAR antibody mAbEDAR1 or with PBS. 
 
 
Figure 5. Edar activation stimulates sebum production. (a) Schematic of experimental schedule. (b) 
Appearance of 9 weeks-old EdaTa mice treated with EDAR agonist antibodies, PBS or the unrelated 
antibody Aprily2. (c) Thin layer chromatography analysis of sebum extracted from dorsal hair. CE, 
cholesterol ester; WDE, wax diester; TG, triglyceride; C, cholesterol. (d) Quantification of wax diester 
band intensity. Heavy bands are underestimated (non-linear response). n: animals per condition. (e) 
Total sebum quantification of unstimulated WT and EdaTa mice. (f) Quantification of total sebum at 6 
weeks or 12 to 24 weeks (> 6 w) treatment in unstimulated (Ctrls) or stimulated (mAbs) mice. WT 
and EdaTa (Tb) values are pooled. *, p < 0.05. ns, not significant. ***, p < 0.001. Error bars indicate 
SEM. 
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